Opinion of the Transparency Council – levocetirizini dihydrochloridum

At its meeting on 11 July 2022 the Transparency Council adopted opinion No. 102/2022 on reimbursement of medicines containing the active substance levocetirizini dihydrochloridum for indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics.